May 8, 2018 — Today, Socium Therapeutics announced that James E. Galen, PhD joined the company’s Scientific Advisory Board. Dr. Galen has focused on the construction of attenuated bacterial vaccines and their use as live vectors to deliver foreign antigens to the immune system. His work has had broad applications to the development and pre-clinical testing of a variety of live vaccines against both eukaryotic and prokaryotic pathogens, including the etiological agents for malaria, SARS, plague, anthrax, tetanus, enteric fever, and most recently infections caused by Clostridium difficile and Acinetobacter baumannii.
Dr. Galen has been involved in instrumental research on the development of plasmid-based expression systems for delivery of foreign antigens from both prokaryotic and eukaryotic organisms.
He has invented three novel systems: (1) Plasmid stabilization and selection system that removes the need for plasmid selection using antibiotics and guarantees plasmid retention in vivo after introduction into live vector strains, (2) Antigen transport system for export of antigens out to the surface of attenuated Salmonella typhi, and (3) An inducible antigen export system that releases surface antigens into the extracellular milieu via outer membrane vesicles.